BioLight Life Sciences Ltd
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company's ophthalmic product offering and pipeline of product candidates include DiagnosTear's TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination… Read more
BioLight Life Sciences Ltd (BOLT) - Net Assets
Latest net assets as of June 2025: ILA23.59 Million ILA
Based on the latest financial reports, BioLight Life Sciences Ltd (BOLT) has net assets worth ILA23.59 Million ILA as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA26.67 Million) and total liabilities (ILA3.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA23.59 Million |
| % of Total Assets | 88.46% |
| Annual Growth Rate | 2.95% |
| 5-Year Change | -48.85% |
| 10-Year Change | -34.68% |
| Growth Volatility | 270.57 |
BioLight Life Sciences Ltd - Net Assets Trend (2005–2024)
This chart illustrates how BioLight Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioLight Life Sciences Ltd (2005–2024)
The table below shows the annual net assets of BioLight Life Sciences Ltd from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA30.74 Million | +1.46% |
| 2023-12-31 | ILA30.30 Million | -43.57% |
| 2022-12-31 | ILA53.69 Million | -12.58% |
| 2021-12-31 | ILA61.42 Million | +2.18% |
| 2020-12-31 | ILA60.11 Million | -11.80% |
| 2019-12-31 | ILA68.15 Million | -12.40% |
| 2018-12-31 | ILA77.80 Million | +868.70% |
| 2017-12-31 | ILA8.03 Million | -51.06% |
| 2016-12-31 | ILA16.41 Million | -65.13% |
| 2015-12-31 | ILA47.06 Million | +82.85% |
| 2014-12-31 | ILA25.74 Million | +16.41% |
| 2013-12-31 | ILA22.11 Million | -40.79% |
| 2012-12-31 | ILA37.34 Million | +58.57% |
| 2011-12-31 | ILA23.55 Million | +765.06% |
| 2010-12-31 | ILA2.72 Million | -79.54% |
| 2009-12-31 | ILA13.31 Million | +66.15% |
| 2006-12-31 | ILA8.01 Million | -54.75% |
| 2005-12-31 | ILA17.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioLight Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24996500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA11.65 Million | 43.33% |
| Other Comprehensive Income | ILA16.13 Million | 60.00% |
| Other Components | ILA249.07 Million | 926.63% |
| Total Equity | ILA26.88 Million | 100.00% |
BioLight Life Sciences Ltd Competitors by Market Cap
The table below lists competitors of BioLight Life Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pacific Software Inc
PINK:PFSF
|
$82.11K |
|
Pharol SGPS S.A
PINK:PHRZF
|
$82.18K |
|
BAOK39
SA:BAOK39
|
$82.19K |
|
SOFTWARE MANSION SPOLKA AKCYJNA
WAR:SWM
|
$82.30K |
|
BTFL39
SA:BTFL39
|
$82.06K |
|
ANTA SPORTS PRODUCT (AS7.SG)
STU:AS7
|
$82.04K |
|
CITIZEN HOLDINGS - Dusseldorf Stock Exchang
DU:CTZ
|
$82.02K |
|
TonnerOne World Holdings Inc
PINK:TONR
|
$82.01K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioLight Life Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 29,776,000 to 26,879,000, a change of -2,897,000 (-9.7%).
- Net loss of 7,142,000 reduced equity.
- New share issuances of 687,000 increased equity.
- Other comprehensive income increased equity by 5,954,000.
- Other factors decreased equity by 2,396,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-7.14 Million | -26.57% |
| Share Issuances | ILA687.00K | +2.56% |
| Other Comprehensive Income | ILA5.95 Million | +22.15% |
| Other Changes | ILA-2.40 Million | -8.91% |
| Total Change | ILA- | -9.73% |
Book Value vs Market Value Analysis
This analysis compares BioLight Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 57.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 7.20x to 57.19x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | ILA45.81 | ILA330.00 | x |
| 2013-12-31 | ILA9.19 | ILA330.00 | x |
| 2014-12-31 | ILA14.21 | ILA330.00 | x |
| 2015-12-31 | ILA13.87 | ILA330.00 | x |
| 2016-12-31 | ILA4.02 | ILA330.00 | x |
| 2017-12-31 | ILA1.89 | ILA330.00 | x |
| 2018-12-31 | ILA19.45 | ILA330.00 | x |
| 2019-12-31 | ILA15.16 | ILA330.00 | x |
| 2020-12-31 | ILA13.04 | ILA330.00 | x |
| 2021-12-31 | ILA13.24 | ILA330.00 | x |
| 2022-12-31 | ILA11.59 | ILA330.00 | x |
| 2023-12-31 | ILA6.41 | ILA330.00 | x |
| 2024-12-31 | ILA5.77 | ILA330.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioLight Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3261.19%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.27x
- Recent ROE (-26.57%) is above the historical average (-63.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 2.43% | 1092.16% | 0.00x | 1.29x | ILA-1.73 Million |
| 2012 | -34.89% | -25684.62% | 0.00x | 1.09x | ILA-17.18 Million |
| 2013 | -149.82% | -22971.95% | 0.00x | 2.73x | ILA-20.09 Million |
| 2014 | -81.34% | -2455.05% | 0.02x | 1.42x | ILA-25.94 Million |
| 2015 | -55.59% | -1384.54% | 0.02x | 1.83x | ILA-22.72 Million |
| 2016 | -201.31% | -1033.82% | 0.06x | 3.26x | ILA-22.91 Million |
| 2017 | -282.95% | -1427.63% | 0.05x | 4.06x | ILA-17.87 Million |
| 2018 | 79.42% | 1773.39% | 0.04x | 1.10x | ILA57.15 Million |
| 2019 | -18.28% | -4239.39% | 0.00x | 1.09x | ILA-19.48 Million |
| 2020 | -22.60% | -43167.74% | 0.00x | 1.09x | ILA-19.30 Million |
| 2021 | 0.63% | 12733.33% | 0.00x | 1.06x | ILA-5.69 Million |
| 2022 | -14.76% | -12455.56% | 0.00x | 1.07x | ILA-13.16 Million |
| 2023 | -87.39% | -22050.85% | 0.00x | 1.12x | ILA-29.00 Million |
| 2024 | -26.57% | -3261.19% | 0.01x | 1.27x | ILA-9.83 Million |
Industry Comparison
This section compares BioLight Life Sciences Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $66,155,405
- Average return on equity (ROE) among peers: -98.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioLight Life Sciences Ltd (BOLT) | ILA23.59 Million | 2.43% | 0.13x | $82.11K |
| BioLine RX Ltd (BLRX) | $11.68 Million | -151.01% | 0.71x | $104.99K |
| Can Fite Biopharma Ltd (CANF) | $13.07 Million | -28.13% | 0.42x | $137.32K |
| Clal Biotechnology Industries Ltd (CBI) | $274.45 Million | -30.26% | 0.55x | $130.78K |
| DNA Biomed Solns (DNA) | $28.18 Million | -136.72% | 0.30x | $392.94K |
| G.F.C Green Fields Capital Ltd. (GFC-M) | $131.71 Million | 3.17% | 0.24x | $402.34K |
| Matricelf Ltd (MTLF) | $2.80 Million | -153.82% | 1.12x | $388.41K |
| Plantarc Bio Ltd (PLNT) | $1.19 Million | -192.87% | 0.81x | $19.61K |